Literature DB >> 16987076

Expression of human CD226 on T cells and natural killer cells and of soluble CD226 in plasma of HIV-1-infected Chinese patients.

Xiaohui Ye1, Zining Zhang, Yongjun Jiang, Xiaoxu Han, Yanan Wang, Min Zhang, Jing Liu, Wenqing Geng, Di Dai, Wanying Shi, Hong Shang.   

Abstract

Our objective was to detect the expression of CD226 on natural killer (NK) cells and T cells, and to measure the amount of soluble CD226 in the plasma of HIV-infected individuals, in order to evaluate the function of CD226 in HIV infection. Thirty-four untreated HIV-1-infected patients and 26 normal controls were enrolled and three-color flow cytometry was used to detect the expression of CD226 on T lymphocytes and NK cells in whole blood samples taken from the patients and normal controls, and in HIV-1SF33-infected peripheral blood mononuclear cells (PBMCs). An enzymelinked immunosorbent assay (ELISA) was used to detect the level of soluble CD226 in the plasma of HIV-infected patients and normal controls and in the supernatant of HIV-1SF33-infected cells. The level of CD226 expression on CD3+, CD4+, and CD8+ T cells and on CD3- CD16+ NK cells of HIV-infected patients was significantly higher than that of normal controls (p < 0.01). The level of soluble CD226 in the plasma of HIV-infected patients was also significantly higher than that of normal controls (p < 0.01). After stimulation with HIV-1SF33, the level of CD226 expression on CD3+ T cells and CD3- CD16+ NK cells of cultured PBMCs reached peak values at 48 h, which was earlier than in uninfected control cells (72 h). The level of soluble CD226 in the supernatant of HIV- 1SF33-infected cell culture was higher than that of uninfected cells, and the level of soluble CD226 in the supernatant of HIV-1SF33-infected cells reached the peak value at 72 h, which was earlier than in uninfected control cells (96 h) but later than the time of peak CD226 expression on CD3+ T lymphocytes (48 h). We conclude that CD226 may be involved in the immune response to HIV infection and that further experiments are needed to find the function of CD226 in the pathogenesis of HIV infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16987076     DOI: 10.1089/vim.2006.19.576

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  6 in total

1.  The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR.

Authors:  Giulia Matusali; Marina Potestà; Angela Santoni; Cristina Cerboni; Margherita Doria
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  CD226 protein is involved in immune synapse formation and triggers Natural Killer (NK) cell activation via its first extracellular domain.

Authors:  Shengke Hou; Kuikui Ge; Xiaodong Zheng; Haiming Wei; Rui Sun; Zhigang Tian
Journal:  J Biol Chem       Date:  2014-01-22       Impact factor: 5.157

3.  Establishment of an enzyme-linked immunosorbent assay system for determining soluble CD96 and its application in the measurement of sCD96 in patients with viral hepatitis B and hepatic cirrhosis.

Authors:  J Gong; C Zhu; R Zhuang; C Song; Q Li; Z Xu; Y Wei; K Yang; A Yang; L Chen; B Jin
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

4.  Differential expression of CD96 surface molecule represents CD8⁺ T cells with dissimilar effector function during HIV-1 infection.

Authors:  Emily M Eriksson; Chris E Keh; Steven G Deeks; Jeffrey N Martin; Frederick M Hecht; Douglas F Nixon
Journal:  PLoS One       Date:  2012-12-13       Impact factor: 3.240

5.  CD226 reduces endothelial cell glucose uptake under hyperglycemic conditions with inflammation in type 2 diabetes mellitus.

Authors:  Yuan Zhang; Tian Liu; Yu Chen; Zilong Dong; Jinxue Zhang; Yizheng Sun; Boquan Jin; Feng Gao; Shuzhong Guo; Ran Zhuang
Journal:  Oncotarget       Date:  2016-03-15

Review 6.  Negative Regulation and Protective Function of Natural Killer Cells in HIV Infection: Two Sides of a Coin.

Authors:  Yu Sun; Jie Zhou; Yongjun Jiang
Journal:  Front Immunol       Date:  2022-03-07       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.